Clinical Trials
Clinical Trials
Renal Impairment Study Designs Trends, Optimization, Adaptive Approach. A Review.
Drug-Drug Interactions - What you Should Know
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
the study of Drug-Drug Interactions
ISSUE NO. 10 — Tackling Early-Phase Development Challenges with Effective First-in-Human Studies
First-in-Human (FIH) trials in the early phases of drug development represent a critical
milestone in the a
Clinical Case Study - First in Human
Clinical Case Study - Randomized Cross Over Efficacy Study Metabolic Disorder
Clinical Case Study - Evaluting Abuse Potential (HAP) neuropathic pain medication
Clinical Case Study - Drug-Drug Interactions (DDI) Cardiovascular Medication
Clinical Case Study - FIH Safety and Tolerability Cannabis Extract
Clinical Case Study - 505(b)(2) Regulatory Approval, Multiple NDA-enabling Studies
ISSUE NO. 9 — Cardiac Safety Assessment in Clinical Trials
Electrocardiography (ECG) is an integral part of the new drug regulatory environment.
Mandated by regulatory bodies the world over, the thorough and precise evaluation of a new drug’s cardiac effects is